Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model

Thompson, 2001, T-cell regulation by CD28 and CTLA-4, Nat Rev Immunol, 1, 220, 10.1038/35105024

Carter, 2000, Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, J Exp Med, 192, 1027, 10.1084/jem.192.7.1027

Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, 12, 252, 10.1038/nrc3239

Bhatia, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N Engl J Med, 366, 2455, 10.1056/NEJMoa1200694

Hegde, 2014, MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, 515, 558, 10.1038/nature13904

Gore, 2015, Immunotherapies in Early and Advanced Renal Cell Cancer, Prog Tumor Res, 42, 1, 10.1159/000436988

Choueiri, 2014, PD-1 blockade in renal cell carcinoma: to equilibrium and beyond, Cancer Immunol Res, 2, 1132, 10.1158/2326-6066.CIR-14-0193

Grupp, 2012, The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer, Clin Cancer Res, 18, 2780, 10.1158/1078-0432.CCR-11-1920

Sadelain, 2002, Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor, Nat Biotechnol, 20, 70, 10.1038/nbt0102-70

Riddell, 2015, Engineering CAR-T cells: Design concepts, Trends Immunol, 36, 494, 10.1016/j.it.2015.06.004

Rheingold, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med, 371, 1507, 10.1056/NEJMoa1407222

Huang, 2016, Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials, Eur J Haematol, 96, 389, 10.1111/ejh.12602

Gottschalk, 2014, CAR T cells for solid tumors: armed and ready to go?, Cancer J, 20, 151, 10.1097/PPO.0000000000000032

Pastorekova, 2014, Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors, Front Physiol, 4, 400

Pastorek, 2014, Carbonic anhydrase IX: regulation and role in cancer, Subcell Biochem, 75, 199, 10.1007/978-94-007-7359-2_11

Gigante, 2010, Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment, Eur J Cancer, 46, 3141, 10.1016/j.ejca.2010.07.020

Signoretti, 2010, Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade, Am J Clin Pathol, 134, 873, 10.1309/AJCPPPR57HNJMSLZ

Cooper, 2011, Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies, Cancer Res, 71, 3516, 10.1158/0008-5472.CAN-10-3843

Restifo, 2008, IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy, Blood, 111, 5326, 10.1182/blood-2007-09-113050

Marasco, 2014, Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T-cells expressing a human anti-CAIX chimeric antigen receptor, Mol Ther Oncolytics, 1, 1

Freeman, 2015, PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells, Cancer Immunol Res, 3, 1308, 10.1158/2326-6066.CIR-15-0116

Tamada, 2015, Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy, Cancer Sci, 106, 945, 10.1111/cas.12695

Mulligan, 2006, Exogenous control of mammalian gene expression via modulation of translational termination, Nat Med, 12, 1093, 10.1038/nm1376

Liu, 2015, Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis, Int J Clin Exp Med, 8, 14595

Freeman, 2007, The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection, Nat Immunol, 8, 239, 10.1038/ni1443

Sharpe, 2008, PD-1 and its ligands in tolerance and immunity, Annu Rev Immunol, 26, 677, 10.1146/annurev.immunol.26.021607.090331

Rosenberg, 2007, Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis, J Immunother, 30, 825, 10.1097/CJI.0b013e318156e47e

Antonia, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690

Parren, 2012, Crosstalk between human IgG isotypes and murine effector cells, J Immunol, 189, 3430, 10.4049/jimmunol.1200356

Dong, 2011, B7-h1 expressed by activated CD8 T cells is essential for their survival, J Immunol, 187, 5606, 10.4049/jimmunol.1003976

Marasco, 2015, Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinomaand in a humanized mouse model, Mol Cancer, 14, 119, 10.1186/s12943-015-0384-3

Chen, 2004, NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation, Int J Cancer, 109, 499, 10.1002/ijc.11696

Dhodapkar, 2015, Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes, J Immunol, 194, 950, 10.4049/jimmunol.1401686

Patsch, 2015, Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer, Nature, 520, 373, 10.1038/nature14292

Kronenberg, 2013, Nivolumab plus ipilimumab in advanced melanoma, N Engl J Med, 369, 122, 10.1056/NEJMoa1302369

Darcy, 2013, Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells, Clin Cancer Res, 19, 5636, 10.1158/1078-0432.CCR-13-0458

Wolchok, 2015, Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies, Ann Oncol, 26, 2375, 10.1093/annonc/mdv383

Gratama, 2013, Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity, Mol Ther, 21, 904, 10.1038/mt.2013.17

Gratama, 2007, Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions, Cancer Immunol Immunother, 56, 1875, 10.1007/s00262-007-0330-3

Gratama, 2011, Immune responses to transgene and retroviral vector in patients treated with-engineered T cells, Blood, 117, 72, 10.1182/blood-2010-07-294520

Fry, 2015, 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors, Nat Med, 21, 581, 10.1038/nm.3838

Marasco, 2010, Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology, PLoS One, 5, e9625, 10.1371/journal.pone.0009625

Sodroski, 2000, Paramagnetic proteoliposomes containing a pure, native, and oriented seven-transmembrane segment protein, CCR5, Nat Biotechnol, 18, 649, 10.1038/76501

Salfeld, 2007, Isotype selection in antibody engineering, Nat Biotechnol, 25, 1369, 10.1038/nbt1207-1369

Uludag, 2012, A simple and rapid nonviral approach to efficiently transfect primary tissue-derived cells using polyethylenimine, Nat Protoc, 7, 935, 10.1038/nprot.2012.038

Kupper, 2012, Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells, Mol Cancer Ther, 11, 2451, 10.1158/1535-7163.MCT-12-0278

De, 2014, IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples, PLoS One, 9, e96801, 10.1371/journal.pone.0096801